Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
    Meeting Abstract

    Juric, D.; Kalinsky, K.; Turner, N. C.; Jhaveri, K. L.; Schmid, P.; Loi, S.; Saura, C.; Im, S. A.; Sunpaweravong, P.; Li, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Meeting Abstract

    Pernas, S.; Im, S. A.; Hattori, M.; Xu, B.; Wang, S.; Lu, Y. S.; Borges, G.; Tsurutani, J.; Jhaveri, K. L.; Zhang, Q. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial
    Meeting Abstract

    Jhaveri, K. L.; Hurvitz, S. A.; Brufsky, A.; Bose, R.; de Miguel, M. J.; Evron, E.; Unni, N.; Reid, S. A.; Quinn, D. I.; Mahalingam, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer
    Meeting Abstract

    Saura, C.; Sanz, L.; Kim, J.; Jhaveri, K. L.; Guerrero, A.; Ortega, P. T.; Schott, A. F.; Curigliano, G.; Perez, C. A.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation
    Meeting Abstract

    Goetz, M. P.; Wander, S. A.; Bachelot, T.; Batist, G.; Cortes, J.; Cristofanilli, M.; Curigliano, G.; De Nonneville, A.; Gal-Yam, E. N.; Jhaveri, K. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Meeting Abstract

    Saura, C.; Cortés, J.; Modi, S.; Kim, S. B.; Hamilton, E. P.; Hurvitz, S. A.; Krop, I. E.; Curigliano, G.; Iwata, H.; Im, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030
    Meeting Abstract

    Marta, G. N.; Chu, X.; Mukhopadhyay, S.; Abramson, V. G.; Brufsky, A.; Stringer-Reasor, E. M.; Dent, S. F.; Traina, T. A.; Carey, L. A.; Rimawi, M. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study
    Meeting Abstract

    Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Pegram, M. D.; Calfa, C.; Chen, C.; Cortés Salgado, A.; Heeke, A. L.; Kang, I.; Pistilli, B.; Pohlmann, P. R.; Rugo, H. S.; Saura, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save